Generally, the germline EGFR mutations reported could be oncogenic if alone [42–44, 46, 69]; and the growth potential would be enhanced dramatically when co-occurring with a secondary activating mutation [42–44, 46, 69], which may indicate a ‘second-hit’ proliferative advantage in the tumours [42, 70]. This evidence concerns the gene EGFR and neoplasm.